COHANCE : USFDA INSPECTION COMPLETED AT API FACILITY

• USFDA inspected the company's API manufacturing facility at Jaggaiahpet, Andhra Pradesh from 14 September to 19 September 2026 • The inspection concluded with a Form FDA 483 containing five observations • The company has initiated appropriate corrective and preventive actions (CAPA) • Response will be submitted within the stipulated timeline Impact: Neutral (Routine regulatory inspection completed; company initiating CAPA and response.)

Cohance Lifesciences Limited

Open attachment

← Back to feed